IGF1 and metabolic dysfunction-associated steatotic liver disease: Subsequent studies have shown that IGFBP2 blunts the stimulation of de novo lipogenesis by IGF1 in hepatocytes from healthy mice or mouse models with fatty liver disease, suggesting that lower levels of IGFBP2 may exacerbate the development of MASLD (23).